The Global PARP Inhibitor Biomarkers Market is estimated to be valued at US$ 907.1 million in 2023 and is expected to exhibit a CAGR of 24.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.Market Overview:The PARP Inhibitor Biomarkers market is experiencing significant growth due to the increasing incidence of cancer worldwide. PARP...
PARP (Poly ADP-Ribose Polymerase) inhibitor biomarkers are used for the stratification of patients with certain cancers like breast and ovarian cancer into those likely to respond to PARP inhibitor treatment and those unlikely to respond. They play an important role as companion diagnostics alongside PARP inhibitors drugs to identify patients with homologous recombination deficiency (HRD)...
PARP inhibitor biomarkers are essential diagnostic tools for cancer treatment and identifying response rates to PARP inhibitor therapies. PARP inhibitors are increasingly used for the treatment of metastatic cancers with BRCA mutations. These inhibitors are primarily used for treating cancers like ovarian, breast, and prostate cancers. Rising cancer prevalence worldwide drives the adoption of...